Melane Sampson, Author at BioTuesdays

Developments

Annovis launches OLE study in Parkinson’s disease

Annovis Bio (NYSE: ANVS) has announced it will begin an open-label extension (OLE) study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in Parkinson’s disease (PD) patients. The study aims...

December 19, 2025

Developments

Altimmune’s pemvidutide achieves key measures of success at 48 weeks in MASH trial

Altimmune (NASDAQ: ALT) has announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patients with metabolic dysfunction-associated...

December 19, 2025

Executive Moves

PureTech appoints Robert Lyne as CEO

PureTech Health (NASDAQ: PRTC; LSE: PRTC) has announced the appointment of Robert Lyne as chief executive officer (CEO), and member of the board of directors, effective immediately. Mr. Lyne has served as interim CEO...

December 18, 2025

Developments

Ovid reports results of OV350 IV study

Ovid Therapeutics (NASDAQ: OVID) has announced that its Phase 1 study of OV350—the first direct activator of potassium chloride cotransporter 2 (KCC2) to be dosed in humans—administered intravenously (IV), has met its...

December 18, 2025

Developments

Tiziana doses first patient in Phase 2 trial of intranasal foralumab in AD

Tiziana Life Sciences (NASDAQ: TLSA) has announced that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease...

December 17, 2025

Developments

VYNE and Yarrow announce merger agreement

VYNE Therapeutics (NASDAQ: VYNE) has announced that it has entered into a merger agreement with closely held Yarrow Bioscience, with the combined companies expected to operate as Yarrow Bioscience under the ticker...

December 17, 2025

Uncategorized

CERo reveals updates to Phase 1 trial of CER-1236 in AML

CERo Therapeutics (OTCQB: CERO) has announced advancements to the CertainT-1 trial focused on patients with acute myeloid leukemia (AML). According to CERo, following completion of the dose-limiting toxicity (DLT)...

December 17, 2025

Developments

FDA grants fast track designation for Adagene’s muzastotug

Adagene (NASDAQ: ADAG) has announced that the FDA has designated muzastotug, in combination with Merck’s (NYSE: MRK) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), as a fast track product for adult patients with...

December 16, 2025

Executive Moves

Brooke Story joins PolyPid as chair of the BOD

PolyPid (NASDAQ: PYPD) has announced the appointment of medtech leader Brooke Story as chair of the board of directors (BOD), effective December 11, 2025. Ms. Story brings more than 25 years of leadership experience in...

December 16, 2025

Feature

Aqua Medical reversing the metabolic clock with innovative vapor ablation technology

Closely held Aqua Medical is advancing therapy for gastrointestinal (GI) and metabolic diseases—including Type 2 diabetes—using its disruptive, transoral, outpatient vapor-based endoscopic ablation platform.

December 16, 2025

Author - Melane Sampson

Annovis launches OLE study in Parkinson’s disease

Altimmune’s pemvidutide achieves key measures of success at 48 weeks in MASH trial

PureTech appoints Robert Lyne as CEO

Ovid reports results of OV350 IV study

Tiziana doses first patient in Phase 2 trial of intranasal foralumab in AD

VYNE and Yarrow announce merger agreement

CERo reveals updates to Phase 1 trial of CER-1236 in AML

FDA grants fast track designation for Adagene’s muzastotug

Brooke Story joins PolyPid as chair of the BOD

Aqua Medical reversing the metabolic clock with innovative vapor ablation technology

Subscribe